EL7.AI
StocksMedium•16 November 2026•
3 min read

Kyntra Bio Posts $0.04 Per-Share Income and $1.762 Million in Third-Quarter Revenue

Key Facts

1Income from continuing operations was $157,000, or $0.04 per share, in the third quarter of 2026.
2Revenue was $1.762 million in the third quarter of 2026, compared with $1.076 million a year earlier.
3Cash, investments and accounts receivable totaled $44.1 million on September 30, and the company expects them to fund operations through 2028.
4The company expects to save more than $20 million in operating expenses in 2027 and 2028 after halting development of two programs.

Kyntra Bio reported third-quarter results on November 16, posting net income from continuing operations of $157,000, or $0.04 per basic and diluted share. Total revenue was $1.762 million for the three months ended September 30, 2026. The market's average revenue estimate was $2 million, according to an Associated Press report, meaning revenue fell short of expectations. The reported earnings-per-share figure alone does not establish that the company exceeded analysts' expectations. The results put the annual income turnaround alongside operating pressures and new strategic choices announced by the company.

Total revenue rose from $1.076 million in the third quarter of 2025 to $1.762 million in the corresponding period of 2026. Most of the latest quarter's revenue came from drug products, which totaled $1.663 million, compared with $957,000 a year earlier. By contrast, development and other revenue fell to $99,000 from $119,000. Year over year, the company posted income from continuing operations of $157,000, after a loss of $13.146 million in the third quarter of 2025. Per-share results swung from a $3.25 loss from continuing operations in the comparable period to income of $0.04 in the latest quarter.

The swing to net income was not accompanied by an improvement in operating results: the operating loss was $12.865 million in the third quarter of 2026, compared with a loss of $5.411 million a year earlier. Research and development expenses rose to $8.266 million from $1.209 million in the corresponding period. The company said it halted development of its FG-3246 and FG-3180 programs after preliminary results from a prespecified interim analysis did not meet the efficacy level needed to continue development. Kyntra Bio expects ending the study to save more than $20 million in operating expenses during 2027 and 2028. The decision is part of a shift in development priorities as the company seeks to advance roxadustat.

Cash and cash equivalents, investments and accounts receivable totaled $44.1 million on September 30, 2026. The company said it expects these resources to be sufficient to fund its operating plans through 2028. Liquidity, investments and accounts receivable totaled $95.7 million on June 30, according to second-quarter results. In that quarter, the company posted income from continuing operations of $12 million, or $2.96 per share, despite recording negative revenue of $1.5 million. An August amendment to the royalty financing agreement also reduced the cap on total payments from $125 million to $65 million, while leaving future royalty-linked payments of no more than $15 million.

The company plans to begin a pivotal Phase 3 trial of roxadustat for anemia in lower-risk myelodysplastic syndrome patients with high transfusion burden in the first quarter of 2027. It tied the trial's start to securing a strategic partnership or raising external financing. In August, the stated target was to begin the trial in the fourth quarter of 2026, before the timing was updated to the first quarter of 2027 with a financing or partnership condition. Management is scheduled to hold a conference call and webcast to discuss results and provide a business update on November 16 at 5:00 p.m. Eastern Time. Ahead of the results announcement, KYNB shares fell 4.18% in the November 13 session, closing at $3.44.